This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
The company’s main area of focus is cystic fibrosis (CF). The company’s lead marketed products are Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor), Symdeko/Symkevi (tezacaftor in combination with ivacaftor), Orkambi (lumacaftor in combination with ivacaftor) and Kalydeco (ivacaftor), which are collectively approved to treat the majority of the people with CF in North America, Europe and Australia. Trikafta, Vertex’s triple combination regimen, was approved by the FDA in October 2019 for the treatment of CF in people aged 12 years and older who have at least one F508del mutation. Kaftrio (brand name of Trikafta in EU) was approved in the European Union in August 2020. It is also being evaluated in younger patients in the United States. With approval of Trikafta, Vertex can address a significantly larger CF patient population — almost 90% of patients with CF — in the future. Meanwhile, Vertex is pursuing genetic therapies to address the remaining 10% of CF patients. While CF remains the main area of focus, Vertex is also developing treatments for sickle cell disease, thalassemia and pain management.
Can AbbVie (ABBV) Spring a Surprise This Earnings Season?
by Zacks Equity Research
AbbVie Inc. (ABBV) is slated to release fourth-quarter and full-year 2016 earnings results before the opening bell on Jan 27.
Why Vertex (VRTX) Might Surprise This Earnings Season
by Zacks Equity Research
Vertex (VRTX) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.
Will These 5 Drug Stocks Be Big Winners in the Q4 Earnings Season?
by Arpita Dutt
The Q4 earnings season has started on a good note with both earnings and revenue growth improving compared to recent quarters.
Concert's (CNCE) CTP-656 Gets Orphan Drug Status in U.S.
by Zacks Equity Research
Concert Pharmaceuticals, Inc. (CNCE) announced that the FDA has granted orphan drug designation to its candidate CTP-656 for the treatment of cystic fibrosis.
4 Drug Stocks Poised to Surprise this Earnings Season
by Zacks Equity Research
Market sentiment seems to be improving courtesy of raised outlooks, new product approvals and encouraging pipeline updates.
Vertex Pharma (VRTX) Q4 Earnings: Stock Likely to Beat?
by Zacks Equity Research
We expect biotech company Vertex Pharmaceuticals, Inc. (VRTX) to beat expectations when it reports fourth-quarter 2016 and full-year earnings results on Jan 25, after the market closes.
Concert Offers Update on Cystic Fibrosis Drug, Stock Down
by Zacks Equity Research
Concert Pharmaceuticals, Inc. (CNCE) provided update on the development plan of its next generation CFTR potentiator, CTP-656, for the treatment of cystic fibrosis in the U.S. and Europe.
Why Vertex Pharmaceuticals (VRTX) Could Be Positioned for a Surge
by Zacks Equity Research
Vertex Pharmaceuticals (VRTX) has seen positive earnings estimate revisions for the current quarter and year, in addition to decent short-term price momentum.
Merck KGaA, Vertex Announce Tie-Up for Oncology Programs
by Zacks Equity Research
Merck (MKGAF) and Vertex (VRTX) collaborated for the development and commercialization of four research and development programs for the treatment of cancer.
Biotech Stock Roundup: ARIAD to be Acquired for $5.2B, Vertex Outlook Falls Short
by Arpita Dutt
Several licensing deals and agreements were announced this week including the $5.2 billion ARIAD (ARIA) acquisition.
Vertex Pharma Issues Disappointing 2017 Orkambi Outlook
by Zacks Equity Research
Vertex Pharmaceuticals Incorporated (VRTX) announced preliminary financial results for 2016 and issued a financial outlook for 2017 on Jan 8, ahead of a Jan 9 presentation at the JP Morgan healthcare conference in San Francisco.
Biotech Stock Roundup: Inotek Plunges on Pipeline Setback, Kite Files IND for Study Initiation
by Arpita Dutt
Although this was a relatively slow week for the biotech sector, Inotek (ITEK) made it to the headlines on disappointing data on its lead pipeline drug.
Is Vertex Pharma (VRTX) Poised for a Turnaround in 2017?
by Zacks Equity Research
Vertex Pharmaceuticals, Inc.'s (VRTX) main therapeutic area of focus is cystic fibrosis (CF). Presently, the company markets two medicines for the disease, Kalydeco and Orkambi.
Regeneron vs. Vertex: Which Stock is a Better Pick?
by Arpita Dutt
Both Regeneron (REGN) and Vertex look set for a rebound in 2017 after a tough and challenging 2016.
Biotech Stock Roundup: FDA Nod for Biogen/Ionis Drug, Seattle Genetics Hit by Clinical Hold
by Arpita Dutt
Biogen (BIIB) and Ionis got an early Christmas gift with the FDA approving their spinal muscular atrophy drug within three months of regulatory filing.
Stock Market News for December 27, 2016
by Zacks Equity Research
Major U.S. benchmarks ended the last trading session ahead of Christmas holiday on a positive note as investors continued to cheer Trump's promises.
5 Toxic Stocks to Remove from Your Portfolio or Play Short
by Zacks Equity Research
Elevated price levels of toxic stocks can be due to either an irrational exuberance associated with them or some serious fundamental lacunae.
Biotech Stock Roundup: Actelion Remains in M&A Spotlight, ASH Data in Focus
by Arpita Dutt
This week, several biotech companies were present at the annual meeting of the American Society of Hematology (ASH) with data on approved and pipeline candidates.
Zacks.com featured highlights: Allegheny Technologies, salesforce.com, United States Steel, Vertex Pharmaceuticals and Continental Resources
by Zacks Equity Research
Zacks.com featured highlights: Allegheny Technologies, salesforce.com, United States Steel, Vertex Pharmaceuticals and Continental Resources
Zacks Industry Outlook Highlights: Amgen, Vertex, Valeant Pharmaceuticals International, Mylan N.V. and Gilead Sciences
by Zacks Equity Research
Zacks Industry Outlook Highlights: Amgen, Vertex, Valeant Pharmaceuticals International, Mylan N.V. and Gilead Sciences
Stock Market News for August 25, 2016
by Zacks Equity Research
by Zacks Equity Research
The biotech segment has been growing well surpassing all expectations.
Vertex Pharmaceuticals Posts Narrower-than-Expected Loss
by Zacks Equity Research
Vertex Pharmaceuticals's (VRTX) third-quarter 2014 loss came in at 56 cents per share wider than the year-ago loss of 46 cents.